Abbott Receives FDA Nod for New Ablation Catheter

Abbott Laboratories announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its latest innovation, a dual ablation catheter. The device is intended for use in cardiac ablation procedures, a common treatment for certain heart rhythm disorders.

This regulatory milestone is seen as a positive development for Abbott's extensive medical device business, particularly its offerings in the cardiovascular space. The dual ablation catheter is designed to provide physicians with an advanced tool for treating arrhythmias, potentially improving patient outcomes and procedural efficiency.

In related news, Giovanni Caforio, the current Chairman and CEO of Abbott, has been appointed as an Operating Advisor to Clayton, Dubilier & Rice (CD&R) funds. This move positions Caforio to contribute his extensive experience in the healthcare and business sectors to the private equity firm.

While this advisory role is separate from his responsibilities at Abbott, it highlights Caforio's recognized leadership within the industry. The appointment to CD&R is effective immediately and will allow him to engage with the firm's investment activities and portfolio companies.